Glauco-Visken en es it fr

Glauco-Visken Brand names, Glauco-Visken Analogs

Glauco-Visken Brand Names Mixture

  • Viskazide 10/25tab (Hydrochlorothiazide + Pindolol)
  • Viskazide 10/50tab (Hydrochlorothiazide + Pindolol)

Glauco-Visken Chemical_Formula


Glauco-Visken RX_link

Glauco-Visken fda sheet

Glauco-Visken msds (material safety sheet)

Glauco-Visken MSDS

Glauco-Visken Synthesis Reference

No information avaliable

Glauco-Visken Molecular Weight

248.321 g/mol

Glauco-Visken Melting Point

167-171 oC

Glauco-Visken H2O Solubility

7880 mg/L

Glauco-Visken State


Glauco-Visken LogP


Glauco-Visken Dosage Forms


Glauco-Visken Indication

For the management of hypertension, edema, ventricular tachycardias, and atrial fibrillation.

Glauco-Visken Pharmacology

Pindolol is a non-selective beta-adrenergic antagonist (beta-blocker) which possesses intrinsic sympathomimetic activity (ISA) in therapeutic dosage ranges but does not possess quinidine-like membrane stabilizing activity. Pindolol impairs AV node conduction and decreases sinus rate and may also increase plasma triglycerides and decrease HDL-cholesterol levels. Pindolol is nonpolar and hydrophobic, with low to moderate lipid solubility. Pindolol has little to no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, pindolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action.

Glauco-Visken Absorption

Rapidly and reproducibly absorbed (bioavailability greater than 95%).

Glauco-Visken side effects and Toxicity

LD50=263 mg/kg (orally in rats). Signs of overdose include excessive bradycardia, cardiac failure, hypotension, and bronchospasm.

Glauco-Visken Patient Information

Glauco-Visken Organisms Affected

Humans and other mammals